IP Library Granted Patent US 11,661,634
Granted Patent B2
US 11,661,634 · App. 17/814,214 · Granted May 30, 2023

Method for producing RNA

Inventors: Florian Von Der Mülbe (Stuttgart, DE); Ladislaus Reidel (Rottenburg am Neckar, DE); Thomas Ketterer (Gomaringen, DE); Lilia Gontcharova (Reutlingen, DE); Susanne Bauer (Bodelshausen, DE); Steve Pascolo (Zurich, CH); Jochen Probst (Wolfschlugen, DE); Andreas Schmid (Sigmaringen, DE)
Assignee: CureVac Manufacturing GmbH
C12Q1/689C12N15/1003C12P19/34C12Q2600/158
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,661,634
App. No.
17/814,214
Granted
May 30, 2023
Kind
B2
Abstract

The present invention relates to a method for producing RNA. In particular, the present invention relates to a method for producing RNA, which is scalable and provides RNA at a high purity. The present invention provides a method for producing RNA under GMP and/or cGMP-compliant conditions. The invention further provides specific processes for use as a quality control in the manufacturing of a template DNA and/or in a method for producing RNA, in particular by in vitro transcription.

Claims (81)

1. A method for producing purified RNA comprising the following steps:

a) (i) providing plasmid template DNA comprising a nucleic acid sequence encoding the RNA sequence, said RNA sequence comprising a 5′ untranslated region (UTR), an open reading frame, a 3′ UTR and a Poly(A) sequence, and (ii) linearizing the plasmid template DNA with an endonuclease to provide a linearized template DNA,

wherein the plasmid template DNA has been purified by chromatography and/or filtration,

wherein the following steps are used to control the quality of the plasmid template DNA or the linearized template DNA of step a):

I) determining the concentration of the plasmid template DNA or the linearized template DNA in a sample;

II) determining the integrity of the plasmid template DNA or the linearized template DNA in a sample;

III) determining the identity of the plasmid template DNA or the linearized template DNA in a sample; and

IV) determining the purity of the plasmid template DNA or the linearized template DNA by determining in a sample comprising the plasmid template DNA or the linearized template DNA: the presence of endotoxin; and/or the presence of bacterial DNA;

b) in vitro transcribing the linearized template DNA in the presence of a cap analog in order to obtain a composition comprising capped RNA,

c) treating the composition with a DNase;

d) purifying the RNA by at least one step of chromatography or filtration to obtain purified RNA, wherein the following steps are used to assess the quality of the purified RNA obtained in step d:

i) determining the concentration of the purified RNA in a sample;

ii) determining the integrity of the purified RNA;

iii) determining the identity of the purified RNA, by reverse transcription (RT)-PCR using the RNA as a template;

iv) determining the purity of the purified RNA, by determining in a sample comprising the RNA the presence of linearized template DNA;

v) determining the poly(A) length of the purified RNA; and

vi) determining the pH of a sample comprising the purified RNA.

2. The method of claim 1 , wherein determining the poly(A) length of the purified RNA comprises a PCR assay.

3. The method of claim 1 , wherein IV) further comprises determining the purity of the plasmid template DNA or the linearized template DNA by determining in a sample comprising the plasmid template DNA or the linearized template DNA: the presence of RNA; the presence of protein; the presence of endotoxin; and/or the presence of bacterial DNA.

4. The method of claim 1 , further comprising prior to step a) purifying the plasmid template DNA by chromatography and filtration.

5. The method of claim 1 , further comprising, prior to step a) culturing bacteria comprising the plasmid template DNA under selective conditions; and isolating the plasmid template DNA from the bacteria.

6. The method of claim 1 , wherein the concentration of the template DNA provided in step a) is determined by photometric measurement.

7. The method of claim 1 , wherein the poly(A) sequence is 50 to 300 adenine nucleotides.

8. The method of claim 1 , wherein the DNase is DNase I.

9. The method of claim 1 , wherein step a) comprises:

I) determining the concentration of the linearized template DNA in a sample;

II) determining the integrity of the linearized template DNA in a sample; and

III) determining the purity of the linearized template DNA in a sample.

10. The method of claim 1 , wherein b) in vitro transcribing the linearized template DNA is in a reaction mixture that includes a cap analog, T7 polymerase, spermidine, an RNAse inhibitor and a HEPES buffer.

11. The method of claim 10 , wherein the reaction mixture includes the cap analog and GTP in a ratio of about 10:1 to 1:1 (cap analog:GTP).

12. The method of claim 1 , wherein b) in vitro transcribing the linearized template DNA is in a reaction mixture that includes a modified nucleotide.

13. The method of claim 12 , wherein the modified nucleotide is 1-methyl-pseudouridine.

14. The method of claim 1 , further comprising determining the presence of plasmid template DNA or linearized template DNA in the purified RNA.

15. The method of claim 1 , wherein ii) determining the integrity of the purified RNA comprises a capillary gel electrophoresis assay.

16. A method for producing purified RNA comprising the following steps:

a) (i) providing plasmid template DNA comprising a nucleic acid sequence encoding the RNA sequence, said RNA sequence comprising a 5′ untranslated region (UTR), an open reading frame, a 3′ UTR and a Poly(A) sequence, and (ii) linearizing the plasmid template DNA with an endonuclease to provide a linearized template DNA,

wherein the plasmid template DNA has been purified by chromatography and/or filtration,

wherein the following steps are used to control the quality of the plasmid template DNA or the linearized template DNA of step a):

I) determining the concentration of the plasmid template DNA or the linearized template DNA in a sample;

II) determining the integrity of the plasmid template DNA or the linearized template DNA in a sample;

III) determining the identity of the plasmid template DNA or the linearized template DNA in a sample; and

IV) determining the purity of the plasmid template DNA or the linearized template DNA by determining in a sample comprising the plasmid template DNA or the linearized template DNA: the presence of RNA; the presence of protein; the presence of endotoxin; and/or the presence of bacterial DNA;

b) in vitro transcribing the linearized template DNA to obtain a composition comprising RNA,

c) treating the composition with a DNase;

d) purifying the RNA by at least one step of chromatography or filtration to obtain purified RNA, wherein the following steps are used to assess the quality of the RNA obtained in step b or the purified RNA obtained in step d:

i) determining the concentration of the RNA or the purified RNA in a sample;

ii) determining the integrity of the RNA or the purified RNA;

iii) determining the identity of the RNA or the purified RNA, by reverse transcription (RT)-PCR using the RNA as a template;

iv) determining the purity of the RNA or the purified RNA, by determining in a sample comprising the RNA the presence of the plasmid template DNA or the linearized template DNA; and

v) determining the pH of a sample comprising the RNA or the purified RNA.

17. The method of claim 16 , wherein the poly(A) sequence is 50 to 300 adenine nucleotides.

18. The method of claim 16 , wherein step b) comprising in vitro transcribing the template DNA in a reaction mixture that includes a cap analog in order to obtain a composition comprising capped RNA.

19. The method of claim 16 , wherein b) in vitro transcribing the template DNA is in a reaction mixture that includes a modified nucleotide.

20. The method of claim 19 , wherein the modified nucleotide is 1-methyl-pseudouridine.

21. The method of claim 16 , wherein step wherein step b) comprises a step of enzymatically capping the RNA.

22. The method of claim 16 , further comprising determining the poly(A) length of the purified RNA.

23. The method of claim 22 , wherein determining the poly(A) length of the purified RNA comprises a PCR assay.

24. The method of claim 16 , further comprising determining the presence of plasmid template DNA or linearized template DNA in the purified RNA.

25. The method of claim 7 , wherein b) in vitro transcribing the linearized template DNA is in a reaction mixture that includes a cap analog, T7 polymerase, spermidine, an RNAse inhibitor and a HEPES buffer.

26. The method of claim 25 , wherein the reaction mixture includes a modified nucleotide comprising 1-methyl-pseydouridine.

27. The method of claim 26 , wherein determining the poly(A) length of the purified RNA comprises a PCR assay.

28. The method of claim 27 , wherein ii) determining the integrity of the purified RNA comprises a capillary gel electrophoresis assay.

29. The method of claim 28 , wherein the reaction mixture incudes the cap analog and GTP in a ratio of about 1:1.

30. A method for producing purified RNA comprising the following steps:

a) (i) providing plasmid template DNA comprising a nucleic acid sequence encoding the RNA sequence, said RNA sequence comprising a 5′ untranslated region (UTR), an open reading frame, a 3′ UTR and a Poly(A) sequence, and (ii) linearizing the plasmid template DNA with an endonuclease to provide a linearized template DNA,

wherein the linearized template DNA has been purified by filtration,

wherein the following steps are used to control the quality of the plasmid template DNA or the linearized template DNA of step a):

I) determining the concentration of the plasmid template DNA or the linearized template DNA in a sample;

II) determining the integrity of the plasmid template DNA or the linearized template DNA in a sample;

III) determining the identity of the plasmid template DNA or the linearized template DNA in a sample; and

IV) determining the purity of the plasmid template DNA or the linearized template DNA by determining in a sample comprising the plasmid template DNA or the linearized template DNA: the presence of endotoxin;

and/or the presence of bacterial DNA;

b) in vitro transcribing the linearized template DNA in the presence of a cap analog in order to obtain a composition comprising capped RNA,

c) treating the composition with a DNase;

d) purifying the RNA by at least one step of chromatography or filtration to obtain purified RNA, wherein the following steps are used to assess the quality of the purified RNA obtained in step d:

i) determining the concentration of the purified RNA in a sample;

ii) determining the integrity of the purified RNA;

iii) determining the identity of the purified RNA, by reverse transcription (RT)-PCR using the RNA as a template;

iv) determining the purity of the purified RNA, by determining in a sample comprising the RNA the presence of linearized template DNA;

v) determining the poly(A) length of the purified RNA; and

vi) determining the pH of a sample comprising the purified RNA.

Assignments (1)
CHANGE OF NAME Recorded Nov 12, 2022
From: CUREVAC REAL ESTATE GMBH
To: CUREVAC MANUFACTURING GMBH
Reel/Frame 061932/0502 →
Continuity (6)
Continuation 17589879 · Jan 31, 2022
Continuation 16891018 · Jun 2, 2020
Continuation 16005131 · Jun 11, 2018
Continuation 15044094 · Feb 15, 2016
Continuation PCTEP2015000959 · May 8, 2015
Related Publication 20230053382A1 · Feb 23, 2023
Cited By (4)
US 12,221,605 US 12,240,873 US 12,385,088 US 12,528,855